China reduces human epilepsy seizures by 92.6 percent in first trial
Chinese researchers report a 92.6 percent drop in seizures during the first human chemogenetic trial for epilepsy.
Trial results show major reduction
The study involved patients with refractory epilepsy who did not respond to standard medications. Participants experienced a significant decrease in seizure frequency after receiving the new treatment. Some individuals saw their attacks completely eliminated during the observation period.
New method avoids brain surgery
Traditional operations for this condition often carry risks of permanent neurological damage. The chemogenetic approach offers an alternative that does not require invasive craniotomy procedures. This technique targets abnormal neural discharges without causing irreversible deficits.
Patients face fewer dangerous attacks
Unpredictable seizures can cause convulsions and loss of consciousness for affected people. The new intervention aims to stop these events before they sweep through brain circuits. Results indicate the method works for a third of patients worldwide who are unresponsive.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.